SLC5A2 and polycystic ovary syndrome: Newer medications targeting insulin sensitivity, such as incretin mimetics and Sodium/glucose cotransporter 2 (SGLT2) inhibitors, have emerged as effective options for managing metabolic dysfunction in PCOS, potentially reducing cardiovascular risks (13).